
MIST Stock Forecast & Price Target
MIST Analyst Ratings
Bulls say
Milestone Pharmaceuticals is poised for growth with its FDA-approved drug Cardamyst for the treatment of PSVT. The company's focus on expanding into the Chinese market and conducting clinical trials for additional indications shows potential for increased revenue and market share. However, challenges in adoption and insurance coverage may affect its success in the US market.
Bears say
Milestone Pharmaceuticals is heavily dependent on its sole product, Cardamyst, and its success in the market. With limited diversification and a relatively small market size compared to its U.S. counterpart, the company's revenue growth and potential profitability could be constrained. Additionally, the success of its current and future pipeline products may be uncertain and could increase the company's financial and commercial risks. And, with a relatively high valuation and a need for continued investment to drive growth, there are concerns about potential dilution risk in the future.
This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
MIST Analyst Forecast & Price Prediction
Start investing in MIST
Order type
Buy in
Order amount
Est. shares
0 shares